Skip to content
Decision-ready map
• Mission goal: deliver benefit safely and equitably
• Risk: burns/pigment harm may be higher in some skin tones
• Program levers: procurement + training + incident reporting
• Sustain trust: transparency and rapid response
(1) What it is
Mission-driven programs may deploy light-based therapies (PBM for wound care/pain, UV phototherapy for skin disease, LED tools for outreach) because they can be noninvasive and scalable. Evidence indicates adverse-event risk—especially unintended heating—can differ across skin tones under some protocols. Programs that deploy devices without skin-tone-aware protocols risk preventable harm and loss of trust.
(2) Who it helps
This brief supports organizations that procure and deploy light-therapy devices, train frontline users, publish guidance, or fund programs. It is relevant to community NGOs, consumer safety groups, and foundations.
(3) What evidence exists
A cohort study reported increased photosensitivity and substantially higher odds of clinically visible thermal injury for darker skin under a dual-wavelength low-power laser protocol (https://doi.org/10.1111/phpp.70042). Reviews emphasize higher melanin can increase vulnerability to laser/light complications without parameter adaptation (https://doi.org/10.4103/ijdvl.IJDVL_88_17) and IPL complication reviews document burns and pigment changes (https://doi.org/10.1002/der2.57). FDA guidance exists for PBM devices marketed with medical purposes (FDA webpage).
(4) Translation barriers
Programs often buy devices based on cost/availability rather than validated safety across diverse users. Training may focus on “how to use” rather than “how to prevent overheating and stop safely.” Field conditions vary and can change risk (heat, humidity, hydration, limited cooling). Many programs lack incident reporting, so minor burns or pigment changes never become improvement signals.
(5) Equity/safety checks
Require vendors to provide protocol parameter documentation and any stratified safety evidence. Use conservative starting protocols, clear stop rules for heat/pain and erythema, and referral pathways for adverse events. Publish plain-language guidance warning against one-setting-fits-all use. Fund monitoring infrastructure (incident reporting, audits) as part of deployment.
(6) Decision questions
• What outcomes justify using light therapy here, and what harms are unacceptable?
• Is there evidence the device/protocol is safe across the skin tones served?
• What training and stop rules prevent overheating injuries?
• How will the program capture and act on adverse-event data, including pigment changes?
(7) Practical next steps
1) Add procurement requirements: full parameter set, cooling needs, safety labeling, and vendor transparency.
2) Create a one-page SOP and training module emphasizing overheating signals and stop rules.
3) Implement incident reporting capturing skin tone/phototype (as appropriate), device model, parameters, and outcome.
4) Publish transparency: device models used and mitigation steps.
(8) References
https://doi.org/10.1111/phpp.70042
https://doi.org/10.4103/ijdvl.IJDVL_88_17
https://doi.org/10.1002/der2.57
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/photobiomodulation-pbm-devices-premarket-notification-510k-submissions